ESR1 and primary cutaneous T-cell non-Hodgkin lymphoma: Nine drugs had five supporting studies: the second-generation antipsychotic medications aripiprazole and risperidone, the tyrosine kinase inhibitors sunitinib and vandetanib, the histone deacetylase inhibitor vorinostat (used to treat cutaneous T-cell lymphoma), the antidiabetic drug pioglitazone, the selective estrogen receptor modulator tamoxifen, the calcium channel blocker and antihypertensive medication verapamil, and adenosine (used in treating certain types of cardiac arrhythmia).